Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LML134 in Shift Work Disorder
NCT03141086Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LML134 in shift work sleep disorder (SWSD) (2 arms), sponsored by Novartis. Primary endpoint: Mean Sleep Latency Over Two Consecutive Test Nights as Measured by the Multiple Sleep Latency Test at Day 2. Started Jul 2017; status: terminated.
02
Drugs
LML134
03
Conditions
shift work sleep disorder (SWSD)
Beyond the preview
Go deeper on NCT03141086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03141086.